STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] STOBOCLO…
WASHINGTON, July 7, 2025 /PRNewswire/ — Paralyzed Veterans of America Chief Executive Officer Carl Blake releases statement following the Department of…